Dacla® is a Direct-Acting Anti-viral (DAA) and is indicated in combination with other drugs for the treatment of chronic hepatitis C virus (HCV) infection in adults For activity in depending on the hepatitis C virus (HCV) genotype,
DCI | DACLATASVIR |
---|---|
Dosage | 60 mg |
Trade name | DACLA® |
Name of the originator | DACLINSA® |
Presentation | 28 tablets |
Specialty | Hépatologie-AAD |